Soleno Therapeutics, Inc.

Thank you.

Greetings and welcome to the Celeno Therapeutics first quarter 2025 earnings conference call. At this time, note that all participants are in a listen-only mode. Should you require operator assistance, please press star zero on your telephone keypad. A question and answer session will follow the formal presentation. You may press star 1 at any time to be placed into the question queue, and we ask that you please ask one question and one follow-up, then return to the queue. As a reminder, this conference is being recorded. It is now my pleasure to turn the call over to Brian Ritchie of LifeSci Advisors. Please go ahead, Brian.

Thank you, Operator. Good afternoon, everyone, and thank you for joining us to discuss Salino Therapeutics' first quarter 2025 financial and operating results. Please note, we'll be making certain forward-looking statements today. We refer you to Celeno's SEC filings for a discussion of the risks that may cause actual results to differ from the forward-looking statements. On the call with me today from Celeno are Anish Bhatnagar, Celeno's Chairman and Chief Executive Officer, Meredith Manning, Celeno's Chief Commercial Officer, and Jim McInnis, Spilano's Chief Financial Officer. Anish will begin with a review of the company's progress during the first quarter and subsequent period, including FDA approval of ICAT-XR and commercial launch. Meredith will then review the company's commercial progress to date, and Jim will cover the company's financial statements for the first quarter. We will then open the call for questions. With that, I will now turn the call over to Anish.